Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...
Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...
Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their ...
Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...
Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
Novo Nordisk (NVO) stock plunges while Eli Lilly (LLY) gains as Danish drugmaker posts Phase 3 results for next-gen weight ...
A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss ...
Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...
19h
Novo Nordisk A/S (NVO) announced Friday that its experimental obesity drug CagriSema demonstrated superior weight loss in adults with ...
Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback